Losartan Potassium Tablet
Product Images NDC 62207-741

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 62207-741). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Granules India Ltd, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100mg-30s-label (100mg 30s Label)

This text provides information about a medication containing 100 mg of losartan potassium, USP. It includes storage instructions, dosage information, manufacturing details, and distribution information. The medication is in tablet form and comes in a container with 30 tablets.*

FDA Label Image

25mg-30s-label (25mg 30s Label)

This is a description of a medication containing 25 mg of losartan potassium. It is advised to store the tablets at 25°C (77°F) with excursions permitted between 15 to 30°C (59 to 86°F). The packaging should be kept tightly closed and protected from light. The usual dosage instructions can be found in the package insert. The medication is manufactured by Granules India Limited in Hyderabad, India, and distributed by Granules Pharmaceuticals Inc. in Chantilly, VA, USA. The box contains 30 tablets of the medication.*

FDA Label Image

50mg-30s-label (50mg 30s Label)

Each tablet contains 50 mg of losartan potassium, USP. The storage instructions recommend keeping the medication at 25°C (77°F) with excursions permitted to 15-30°C (59 to 86°F). It is crucial to protect the tablets from light and to keep the container tightly closed. This medication is manufactured by Granules India Limited in Hyderabad, India, and distributed by Granules Pharmaceuticals Inc. in Chantilly, VA. For dosage information, refer to the package insert.*

FDA Label Image

Fig-1 (Fig 1)

This text provides information about the drug Atenolol and COZAAR, along with a statistic showing an adjusted risk reduction of 13% with a significance level of p=0.021. It also includes a chart showing study months from 6 to 66.*

FDA Label Image

Fig-2 (Fig 2)

This text is discussing the comparison between the effectiveness of Atenolol and Cozaar in reducing the risk of fatal/non-fatal strokes. The adjusted risk reduction for Cozaar is 25%, and the statistical significance is indicated by p=0.001. The study period is indicated from 6 to 66 months.*

FDA Label Image

Fig-3 (Fig 3)

This is a statistical analysis of primary endpoint events within demographic subgroups for patients taking COZAAR and Atenolol. The data includes information on the number of events, rates, hazard ratios, and confidence intervals for different subgroups such as age, gender, race, hypertension, diabetes, and history of cardiovascular disease. The results are presented in a table format showing how each subgroup responded to the two medications, with symbols indicative of sample size. The analysis also mentions that the results were adjusted for baseline Framingham risk score and level of electrocardiographic left ventricular hypertrophy.*

FDA Label Image

Fig-4 (Fig 4)

This description provides information about the percentage of patients with an event (not available) equal to 16.1%, and the associated risk reduction of 16.1% with a p-value of 0.022 at 48 months.*

FDA Label Image

Losartan-structure (Losartan Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.